FGF9 and Patent ductus arteriosus: While Gpc3−/− mutants exhibited a delay in coronary vascular plexus formation and subsequent reduction in sonic hedgehog mRNA expression consistent with GPC3 acting as a co‐receptor for FGF9, it is unclear whether these signaling disruptions could contribute to a PDA phenotype or even whether the PDA observation in this model is biologically significant.